DelveInsight's Hereditary Transthyretin Amyloidosis Market Insights report includes a comprehensive understanding of current ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

University College London's National Amyloidosis Center leads a multinational team reporting that a single infusion of an in ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

Acoramidis reduced the cumulative burden of cardiovascular outcomes at 30 months in patients with transthyretin amyloid ...

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming ...

Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 ...

On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis - ...

One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained ...

Over time, transthyretin amyloidosis (ATTR) can damage the nerves, heart, and other organs. This may lead to complications like heart problems, nerve damage, and trouble with everyday bodily functions ...

With several disease-modifying therapies available for transthyretin amyloid cardiomyopathy (ATTR-CM) -- and more waiting in ...

The streets of Pittsburgh this past weekend were full of runners and walkers for the 48th year of the Great Race.